Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

78 results about "Klotho" patented technology

Klotho is an enzyme that in humans is encoded by the KL gene. This gene encodes a type-I membrane protein that is related to β-glucuronidases. Reduced production of this protein has been observed in patients with chronic renal failure (CRF), and this may be one of the factors underlying the degenerative processes (e.g., arteriosclerosis, osteoporosis, and skin atrophy) seen in CRF. Also, mutations within this protein have been associated with ageing, bone loss and alcohol consumption. Transgenic mice that overexpress Klotho live longer than wild-type mice.

Application of multi-target polypeptide in preparation of medicine for treating organ fibrosis

The invention relates to application of a multi-target polypeptide in preparation of a medicine for treating organ fibrosis, in particular to application of a polypeptide mini-klotho and a gene therapy vector and method thereof in preparation of medicines for treating fibrosis of kidney, liver, lung and other organs. The invention provides the application of mini-klotho in a model for treating kidney, liver and lung fibrosis, and the mini-klotho has a remarkable curative effect and does not have obvious toxic or side effects. Therefore, the mini-klotho disclosed by the invention can be prepared into a medicinal preparation for treating the organ fibrosis.
Owner:NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV

Composition for promoting klotho expression and invention related thereto

To provide a new composition for increasing expression of the Klotho gene and an application thereof.SOLUTION: The present disclosure provides, in one aspect, the following invention: a composition for enhancing expression of the human Klotho / KL gene, the composition comprising at least a portion of a protein belonging to the TNF superfamily or a nucleic acid encoding at least a portion of the protein.SELECTED DRAWING: None
Owner:BIOMIMETICS SYMPATHIES INC

Small extracellular vesicles containing Klotho protein and / or mRNA as well as preparation method and application of small extracellular vesicles

The invention relates to a small extracellular vesicle containing Klotho protein and / or mRNA as well as a preparation method and application of the small extracellular vesicle. The preparation method of the small extracellular vesicle comprises the following steps: S1, constructing a recombinant expression vector containing a Klotho protein coding gene; s2, introducing the recombinant expression vector into recipient cells to obtain a receptor cell strain with stable expression of the Klotho gene; and S3, culturing the receptor cell strain, collecting a culture supernatant, and extracting the small extracellular vesicles from the culture supernatant. The small extracellular vesicles containing the Klotho protein and / or mRNA can regulate and control the expression of endogenous Klotho, the expression profile of bioactive molecules in the small extracellular vesicles is also changed, the small extracellular vesicles are rich in various kidney protective proteins, miRNA and other bioactive molecules, and the treatment effect on AKI and AD is remarkably enhanced.
Owner:THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV

CircRNA nano delivery system capable of reversing nucleus pulposus progenitor cell senescence and preparation method and application of circRNA nano delivery system

The invention discloses a circRNA nano delivery system capable of reversing nucleus pulposus progenitor cell senescence and a preparation method and application of the circRNA nano delivery system. The circRNA nano delivery system comprises: a) Klotho circRNA, and b) a liposome, and the liposome comprises a vascular peptide vasculotide, an ionizable lipid molecule, a phospholipid, a PEG lipid, and a steroid. The invention also provides application of the circRNA nano delivery system capable of reversing nucleus pulposus progenitor cell senescence in preparation of drugs for treating intervertebral disc degeneration. The invention provides liposome particles (Vas-Klotho-LNP) which have targeted NPPCs and wrap circRNA, Klotho circRNA is efficiently introduced into the NPPCs through Tie2 agonist peptide, so that rejuvenation of the NPPCs is promoted, ECM synthesis is promoted, and regeneration and repair of intervertebral discs are synergistically promoted in vivo and in vitro.
Owner:SHANDONG UNIV QILU HOSPITAL

Compound for inducing expression of Anti-aging gene klotho and use thereof

The present invention relates to a compound for inducing the expression of the anti-aging gene klotho and a preparation method therefor. The compound represented by Chemical Formula 1, according to the present invention, has an excellent effect of increasing the expression level of the klotho gene which is a gene associated with aging, and thus can be useful for a pharmaceutical composition, cosmetic composition or food composition for preventing skin aging, inhibiting cellular senescence or preventing, treating alleviating a vascular aging-induced disease or a renal disease.
Owner:KLOTHO SCI

Secreted splicing variant of mammal klotho as a medicament for cognition and behaviour impairments

The invention discloses using secreted splicing variant of mammal Klotho (s-KL) as an agent for the prevention and / or treatment of cognitive and / or behaviour impairments. It also refers to gene constructs and expression vectors useful in gene therapy for the delivery of said s-KL variant to the central nervous system of a mammal, in particular a rodent or a human. Pharmaceutical compositions comprising either the protein s-KL or any gene construct for expressing the protein in the CNS are also disclosed.
Owner:UNIVERSITAT AUTONOMA DE BARCELONA +1

Active oligopeptides and their use in the preparation of anti-aging products

PendingCN122325581AKlothoFGF19
This invention relates to the field of cosmetics, and more particularly to active oligopeptides and their application in the preparation of anti-aging products. This invention provides an active oligopeptide with anti-aging activity, the amino acid sequence of which is shown in SEQ ID NO:1 and / or SEQ ID NO:4. This invention also provides an active oligopeptide (β1 and β1c) designed based on computational structural biology, targeting the β-Klotho FGF19 / / FGF21 and receptor-binding arm (RBA) region, and optimized for physicochemical properties, for use in skin anti-aging.
Owner:GUANGZHOU JIYAN COSMETICS TECH CO LTD +1

Method for determining biological activity of FGF21 (fibroblast growth factor 21)

The invention relates to a method for determining the biological activity of FGF21 (Fibroblast Growth Factor Receptor 21), which comprises the following steps: infecting and transfecting HEK293T cells by using an overexpression lentivirus containing FGFR1 and beta-Klotho genes and a reporter gene plasmid containing an SER reaction element so as to obtain a reporter gene-containing cell strain capable of stably expressing FGFR1, beta-Klotho and SRE; after FGF21 stimulation is added, the expression of a luciferase reporter gene at the downstream of the SER-containing promoter is activated; after co-incubation culture, adding a luciferase substrate, and fitting a four-parameter curve according to a measured reporter gene signal value, so as to determine the biological activity of the FGF21. According to the method provided by the invention, the test period is shortened to 24 hours, the detection sensitivity for FGF21 can reach a nanogram level and is improved by 1000 times compared with that of a traditional glucose oxidation method, and the result is consistent. The method provided by the invention can be used for evaluating the biological activity of FGF21 and analogues thereof as candidate drugs for treating metabolic diseases such as diabetes mellitus and NASH, and plays an important guiding role in quality control in research, development and production of FGF21 drugs.
Owner:WENZHOU MEDICAL UNIV

Culture medium for improving Klotho protein secreted by mesenchymal stem cells and application of culture medium

The invention provides a culture medium for improving Klotho protein secreted by mesenchymal stem cells and application of the culture medium, and particularly, the culture medium comprises a basic culture medium, statins and a ROCK inhibitor. The culture medium can effectively improve the Klotho protein secretion level of the mesenchymal stem cells, does not affect the biological activity of the mesenchymal stem cells, and ensures the biological function integrity of the mesenchymal stem cells; meanwhile, operation is easy, cost is low, and good clinical application value is achieved.
Owner:CELLXPERT BIOTECHNOLOGY CORP +1

Bifunctional recombinant protein GIK for regulating glycolipid metabolism and resisting aging and preparation method therefor

Provided are a bifunctional recombinant protein GIK for regulating the glycolipid metabolism and resisting aging, and a preparation method therefor. The recombinant protein GIK comprises an N-terminus, a middle section and a C-terminus. The N-terminus is an optimized human GLP-1 polypeptide having an amino acid sequence of SEQ ID NO: 1; the middle section is an Fc region of human IgG4 having an amino acid sequence of SEQ ID NO: 2; and the C-terminus is an s-klotho polypeptide having an amino acid sequence of SEQ ID NO: 3. The N-terminus is connected to the middle section via a connecting peptide 1 having an amino acid sequence of SEQ ID NO: 4; the middle section is connected to the C-terminus via a connecting peptide 2 having an amino acid sequence of SEQ ID NO: 5; and a signal peptide of human serum albumin having an amino acid sequence of SEQ ID NO: 7 is introduced at the N-terminus, such that a bifunctional recombinant protein that can be secreted and expressed in mammalian cells is obtained, and the bifunctional recombinant protein has an amino acid sequence of SEQ ID NO: 8.
Owner:SEEBIO BIOTECH (SHANGHAI) CO LTD +1

Anti-βKlotho antibody and its use

The present invention relates to a novel anti-βKlotho antibody and its use.The anti-βKlotho antibody can be used for the treatment of diseases mediated by βKlotho or mediated by βKlotho-FGFR1c-FGF21, particularly metabolic disorders, such as type 1 diabetes, type 2 diabetes, dyslipidemia, nonalcoholic fatty liver disease (NASH), nonalcoholic fatty liver disease (NAFLD), cardiovascular disease, metabolic syndrome, or obesity.
Owner:SHANGHAI JMT BIO TECHNOLOGY CO LTD

Novel compound for inducing expression of anti-aging gene klotho

The present invention relates to novel compounds that induce the expression of the anti-aging gene klotho. The compound of the present invention not only has an excellent effect of increasing the expression amount of Klotho gene, which is a gene related to aging, but also has a protective effect against oxidative stress in retinal pigment epithelial cells (RPE), and thus can be usefully used as a pharmaceutical composition or a health functional food composition for preventing or treating macular degeneration.
Owner:KLOTHO SCI

Klotho mRNA

PCT designated stage expiredWO2024197254A8Cosmetic preparationsPeptide/protein ingredientsKlothoAdenosine
The present invention relates to a Klotho messenger-RNA (mRNA), wherein the mRNA has a 5' CAP region, a 5' un-translated region (5'-UTR), a coding region encoding a Klotho polypeptide, a 3' untranslated region (3'-UTR) and a poly-adenosine Tail (poly-A tail), wherein the Klotho polypeptide comprises the KL1 domain of human Klotho, preferably wherein the coding region encoding the Klotho polypeptide comprises an RNA sequence having at least 80 % sequence identity to SEQ ID NO: 1, and wherein the coding region encoding the Klotho polypeptide preferably has a GC content of at least 54 %.
Owner:ADVANTAGE THERAPEUTICS INC

Genetically modified mesenchymal stem cell expressing Klotho

A genetically modified mesenchymal stem cell including an exogenous nucleic acid including a Klotho encoding region operably linked to a promoter or promoter / enhancer combination, wherein the genetically modified mesenchymal stem cell exhibits increased Klotho expression compared to an unmodified mesenchymal stem cell. Also disclosed are methods of treating a patient including administering a therapeutically effective number of the genetically modified mesenchymal stem cells to the patient. The methods of treatment include treating the patient for a neurodegenerative disease; cancer; organ fibrosis; renal disease; age-related changes of organs or organ systems; to slow, reverse and / or inhibit aging; arteriosclerosis; dementia; diabetes mellitus; erectile dysfunction; autoimmune diseases or autoimmune-related diseases; an inflammatory disease of the lung and sepsis.
Owner:APCETH GMBH & CO KG

Klotho secretory splice variants for prolonged life

The invention provides a polypeptide composed of a sequence SEQ ID NO: 1 or a variant of the polypeptide, the sequence of the variant has at least 85% identity with the sequence SEQ ID NO: 1, and the polypeptide is used for prolonging the life of a subject. The invention also provides a nucleic acid sequence for coding the polypeptide, a gene construct containing the nucleic acid sequence or an expression vector containing the gene construct, which are used for the application. The polypeptides, nucleic acid sequences, gene constructs or expression vectors of the invention may be administered in the form of a pharmaceutical composition with at least one pharmaceutically acceptable excipient, diluent or carrier.
Owner:UNIVERSITAT AUTONOMA DE BARCELONA +2

A GP-pKlotho nano-drug, its preparation method and application

The present invention relates to a GP-pKlotho nano-drug, its preparation method and application. A GP organic molecule is used to wrap the Klotho plasmid, and then this nano-GP-pKlotho drug is used to restore the reduction of Klotho caused by acute / chronic kidney injury and to evaluate the therapeutic effect. After intravenous injection, GP-pKlotho is passively targeted to proximal epithelial cells of the kidney, releases the DNA of Klotho in the cells, and the DNA of Klotho enters the cell nucleus. Compared with the non-injected group, the optimized DNA of Klotho translates into 5-15 times more Klotho mRNA, and the Klotho protein increases by 3-8 times, showing strong therapeutic advantages in treating hypotension in ischemic kidneys and acute and chronic kidney injuries caused by cardiovascular surgery.
Owner:THE SECOND AFFILIATED HOSPITAL ARMY MEDICAL UNIV

Senotherapeutic agents and alpha-klotho polypeptides

This document relates to methods and materials for assessing and / or using one or more senotherapeutic agents. In some cases, methods and materials for determining the efficacy of an anti-senescence treatment in a mammal (e.g., a human) are provided. For example, a level of one or more α-Klotho polypeptides in a sample (e.g., a urine sample) from a mammal (e.g., a human) can be used to determine the efficacy of the one or more senotherapeutic agents. In some cases, methods and materials for treating a mammal (e.g., a human) having a disease or disorder characterized by a reduced level of an α-Klotho polypeptide are provided. For example, one or more senotherapeutic agents and / or one or more inhibitors of a senescence-associated secretory phenotype (SASP) polypeptide can be administered to a mammal (e.g., a human) to increase a level of α-Klotho polypeptides within the mammal.
Owner:MAYO FOUNDATION FOR MEDICAL EDUCATION & RESEARCH

Methods and compositions using klotho-FGF fusion polypepetides

UndeterminedPK200900066A0KlothoCell biology
The present invention is directed to a fusion polypeptide comprising: (a) a polypeptide comprising at least one extracellular subdomain of a Klotho protein; and (b) a polypeptide comprising a fibroblast growth factor. The Klotho fusion .polypeptide of the invention include at least a Klotho protein or an active fragment thereof. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders.
Owner:NOVARTIS AG

Method for estimating the rate of senescent immune cells

The objective is to provide a simple and indirect method for estimating the rate of senescent immune cells (the ratio of immune cells with high SAβgal expression levels among T cells whose surface marker is CD8-positive) using a small amount of blood sample. [Solution] This method estimates the rate of senescent immune cells using the relative expression levels of one or more selected from Granzyme K, α-Klotho, GDF15, PAI-1 (SERPIN1), and ferritin in the blood.
Owner:FUAN KERU

A novel compound that induces expression of the anti-aging gene klotho

The present invention relates to a novel compound that induces the expression of the anti-aging gene klotho. The compound according to the present invention is not only excellent in the effect of increasing the expression level of the klotho gene, which is an aging-related gene, but also has a protective effect against oxidative stress in retinal pigment epithelial cells (RPE), and therefore can be usefully used as a pharmaceutical composition for preventing or treating macular degeneration, or a functional health food composition.
Owner:クロトー サイエンシーズ カンパニー リミテッド

Human Antigen Binding Proteins That Bind Beta-Klotho, FGF Receptors and Complexes Thereof

The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising Q-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) β-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising β-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.
Owner:AMGEN INC

Methods and compositions for improved cognition

ActiveUS12239694B2KlothoCognition
Provided herein are klotho polypeptide compositions and methods for improving cognitive function in an individual comprising treatment of with klotho polypeptides.
Owner:RGT UNIV OF CALIFORNIA

Genetically modified pig, method for producing genetically modified pig, and drug discovery support method

To provide a pig lacking the Klotho gene.SOLUTION: The present invention provides a genetically modified pig (Sus scrofa), where gene manipulation of a fertilized egg results in the knockout of the Klotho gene. The fertilized egg gene manipulation is genome editing. The genome editing includes, as the gRNA sequence, any one or any combination of five specific sequences. The knockout of the Klotho gene is a deletion of one or both alleles. The deletion of one or both alleles of the Klotho gene causes a frameshift mutation. The genetically modified pig exhibits phenotypes of arterial calcification and bone mass reduction.SELECTED DRAWING: Figure 3
Owner:JICHI MEDICAL UNIVERSITY

Application of Klotho in preparation of medicine for treating rheumatoid arthritis

The invention belongs to the field of medicines for treating rheumatoid arthritis, discloses application of Klotho in preparation of medicines for treating rheumatoid arthritis, and particularly relates to application of Klotho in improvement of the inflammatory state of rheumatoid arthritis by regulating a PI3K-AKT signal channel. Klotho can effectively improve clinical inflammation indexes of RA (rheumatoid arthritis). The Klotho can improve the inflammatory state of the RA by adjusting a PI3K-AKT signal channel. Animal experiments prove that Klotho can be applied to treatment of rheumatoid arthritis diseases.
Owner:DALIAN UNIV

Secreted splicing variant of mammal klotho as a medicament for cognition and behaviour impairments

The invention discloses using secreted splicing variant of mammal Klotho (s-KL) as an agent for the prevention and / or treatment of cognitive and / or behaviour impairments. It also refers to gene constructs and expression vectors useful in gene therapy for the delivery of said s-KL variant to the central nervous system of a mammal, in particular a rodent or a human. Pharmaceutical compositions comprising either the protein s-KL or any gene construct for expressing the protein in the CNS are also disclosed.
Owner:UNIVERSITAT AUTONOMA DE BARCELONA +1

Snow tea extract, preparation method and application thereof

This application relates to a snow tea extract, a method for preparing the snow tea extract, and its application. The method for preparing the extract includes the following steps: S1. Mixing pulverized snow tea raw materials with water at a mass ratio of 1:7-15 to obtain a first mixture; S2. Culturing Bacillus licheniformis on a culture medium to obtain a seed culture of the Bacillus licheniformis; S3. Using the seed culture as a fermentation broth, adding it to the first mixture at an inoculum of 1%-5%, and obtaining a fermented mixture after fermentation; S4. Filtering the fermented mixture, and concentrating and drying the filtrate to obtain the snow tea extract. The snow tea extract obtained in this application has an excellent promoting effect on the expression of the klotho gene in human fibroblasts and can be applied in products that improve skin health, filling a gap in the prior art.
Owner:YUNNAN YUNKE CHARACTERISTIC PLANT EXTRACTION LABORATORY CO LTD +2

The human antigen-binding protein (beta)-Klotho, the fibroblast growth factor (FGF) receptor, and its complexes.

PendingTH2501008820ADiseaseKlotho
DEPCT69 This invention provides the composition and methods associated with or derived from antigen-binding proteins that induce fibroblast growth factor 21 (FGF21)-mediated signaling. In some formulations, the antigen-binding protein will specifically bind to (i) beta-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c, or FGFR4; or (iii) a complex composed of beta-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some formulations, the antigen-binding protein will induce FGF21-like signaling. In some formulations, the antigen-binding protein is a fully human antibody, a humanized antibody, or a chimeric antibody, or a binding fragment. and derivatives of such antibodies, and polypeptides that specifically bind to (i) beta-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4;or (iii) complexes containing beta-Klotho and one of FGFR1c, FGFR2c, FGFR3c and FGFR4, other variants providing nucleic acids that encode the antigen-binding proteins, and their fragments and derivatives, and polypeptides, cells containing such polypeptides, methods for generating the antigen-binding proteins, and their fragments and derivatives, and polypeptides, including methods for the treatment or diagnosis of patients suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions;
Owner:AMGEN INC

Enhanced peptide constructs for albumin binding

An albumin binding constructs that enhances the pharmacokinetic performance of therapeutic peptides and proteins, extending their half-lives and reducing administration frequency, is disclosed. The core peptide DICLPRWGCLW (SEQ ID NO: 1) is covalently linked to hydrophilic, flexible glycine-serine (Gly-Ser) linkers of the formula (ggs)xgg where X is 3 to 8 units. These linkers provide strong albumin binding (dissociation constant <20 nanomolar). Some constructs feature the GGSGGSGGSGGRLIEDICLPRGCLWEDD (SEQ ID NO: 4) peptide and allow fusion of active proteins like Klotho, maintaining biological activity and leveraging albumin's extended half-life. Constructs are produced using cellular expression systems (CHO, HEK293, Transgenic Insect Cells) for scalability. These constructs show prolonged half-lives comparable to at least 90% of native albumin. Klotho constructs using the albumin binder demonstrate FGF23 binding dissociation coefficients between 15-30 nanomolar essentially the same as natural Klotho Designed to minimize antigenicity, these constructs improve drug delivery efficacy and patient outcomes.
Owner:FARBER MICHAEL

Anti-renal fibrosis recombinant plasmid ULK, and preparation method and application thereof

PendingCN122357623AKlothoPharmaceutical drug
This invention discloses a recombinant plasmid pULK for treating renal fibrosis, its preparation method, and its applications. The recombinant plasmid pULK carries a Klotho-specific ligand peptide, a GGGGS flexible linker peptide, and a USP2 coding sequence tandemly in a 5'→3' configuration. The amino acid sequences are MASDPLGVVR, GGGGS, and the corresponding USP2 sequence, respectively. The preparation method includes fusion gene design and synthesis, vector linearization, recombinant construction and transformation, and positive clone verification. This plasmid can target and stabilize the Klotho protein, avoiding off-target risks, and can be used to prepare anti-renal fibrosis drugs. It is applicable to various chronic kidney diseases with renal fibrosis, filling a technological gap and demonstrating strong feasibility for clinical translation.
Owner:AFFILIATED HOSPITAL OF GUANGDONG MEDICAL UNIV